Cassava Sciences | PTIE - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 6.65B 787M 2026-06
Amgen USD 5.87B 1.02B 2026-03
Biogen USD 2.12B 307M 2026-06
Cara Therapeutics USD 2.57M 1.11M 2025-03
Cassava Sciences USD -3.96M 1.16M 2025-09
Eisai JPY 183.24B 29.83B 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
Geron USD 50.14M 3.44M 2026-03
J&J USD 18.55B 1.31B 2026-06
Merck USD 12.09B 1.24B 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD -248M 11.29B 2026-06
Roche Holding CHF 22.69B 600M 2026-06